NCT02580305: A trial that was reported late by Suven Life Sciences Limited
This trial has reported, although it was 163 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02580305 |
|---|---|
| Title | A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Sept. 30, 2015 |
| Completion date | Nov. 5, 2019 |
| Required reporting date | Nov. 5, 2022, midnight |
| Actual reporting date | April 17, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 163 |